Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Lilly initiates first-in-human study of LY-3209590 for type 2 diabetes

Dec. 29, 2016

Strongbridge Biopharma acquires U.S. rights to Keveyis from Taro

Dec. 27, 2016

Novelion Therapeutics announces submission of MAA for metreleptin in E.U.

Dec. 23, 2016

Lexicon Pharmaceuticals' inTandem2 phase III study of sotagliflozin meets primary endpoint

Dec. 23, 2016

Positive topline data presented from phase IIb BRID study of biphasic remogliflozin

Dec. 22, 2016

PvP Biologics advancing treatment for celiac disease

Dec. 22, 2016

Medix seeks Mexican clearance to begin phase III study of tesofensine for obesity

Dec. 22, 2016

Diurnal submits European pediatric use marketing authorization application for Infacort

Dec. 21, 2016

Phase Ia/b data for chimeric fibril-reactive mAb 11-1F4 in patients with AL amyloidosis

Dec. 21, 2016

Phase III COMPASS study of volanesorsen in severe hypertriglyceridemia meets primary endpoint

Dec. 20, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...